Obeldesivir, 2647441-36-7 361.35 g/mol C16H19N5O5 [(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl 2-methylpropanoate Q55KCM7PXB; ATV006; UNII-Q55KCM7PXB SCHEME NEXT CN11687449 68% Journal of Medicinal Chemistry (2023), 66(17), 11701-11717 50% WO2023167938  CN115583954  67% WO2022047065 CN113698405 49% https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00750  WO-2022047065-A2 Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that is currently in Phase III trials for the outpatient treatment of COVID-19 in high risk patients.[1][2] The purpose of the isobutyric ester modification on obeldesivir is to improve … Continue reading Obeldesivir